Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 2/3 1

Status

Active not recruiting 3Recruiting 2Not yet recruiting 1Completed 1

Sponsor Class

NIH 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 2Genitourinary 1

Conditions

Melanoma 2Prostatic Neoplasms 1

Interventions

Specimen Handling 116Magnetic Resonance Spectroscopy 94Biopsy 60pembrolizumab 58Carboplatin 57Cisplatin 51Nivolumab 47Cyclophosphamide 40Radiotherapy 39Paclitaxel 37Gemcitabine 34Dexamethasone 34Bevacizumab 31Radiation 30atezolizumab 29Pemetrexed 28venetoclax 25olaparib 25Etoposide 25X-Rays 24Prednisone 23Immunoglobulin G 23Doxorubicin 23Disulfides 23Vincristine 22Lenalidomide 22Leucovorin 21Ipilimumab 21durvalumab 20Taxes 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × sargramostim × 30 days × Clear all
NCT02339571 2026-06-15

A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
600 enrolled
Dermatologic

Melanoma

NCT03600350 2026-06-01

pTVG-HP and Nivolumab in Patients With Non-Metastatic PSA-Recurrent Prostate Cancer

University of Wisconsin, Madison

Phase 2 Active not recruiting
19 enrolled 10 charts
Genitourinary

Prostatic Neoplasms

NCT01134614 2026-05-29

Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 2 Active not recruiting
245 enrolled 8 charts
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡